Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Bioequivalence of Tedizolid Phosphate Oral Formulations
NCT06733688Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tedizolid in acute bacterial skin and skin structure infections (ABSSSI) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity, Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration and 1 more. Started Mar 2022; status: completed.
02
Drugs
tedizolid
03
Conditions
acute bacterial skin and skin structure infections (ABSSSI)
Beyond the preview
Go deeper on NCT06733688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733688.